Finally, NRF2-mediated ROS regulate innate immune responses, TI, thromboembolism, EC activation and death, which are well correlated with the recent clinical trials with NRF2 activators such as sulforaphane and bardoxolone methyl as a potential anti-inflammatory strategy for treating COVID-19 (170). Here, NFE2L2 is linked to COVID-19.